7th Annual

Kinase Inhibitor Chemistry

Shaping Current and Future Development of Kinase Inhibitors

April 20-21, 2016

Kinase Inhibitor Chemistry icon  

Over the past decade, kinase drug discovery has resulted in the rapid and unparalleled development of a new generation of drugs, with over 25 small molecules currently approved by the FDA. As the rate of approval continues to accelerate, developers have found new ways to expand into a deeper portion of target space within the human kinome, moved beyond cancer and into chronic disease indications, particularly within CNS and cardiovascular disorders, as well as increased interest in allosteric modulation and covalently binding compounds. Although kinase drug discovery has already produced an impressive collection of approved therapies, this field remains one of the most vital and burgeoning arenas for pharmaceutical development. 

Cambridge Healthtech Institute’s 7th annual Kinase Inhibitor Chemistry will once again bring together academic and industry leaders to network, collaborate and discuss advances in kinase drug discovery.

Topics may include, but are not limited to:

  • Kinase inhibitors for treatment of cancers, CNS diseases, and cardiovascular disorders 
  • Case studies on immunomodulatory agents and combinations 
  • Emerging strategies for kinase inhibitor discovery and development
  • Novel kinase inhibitor scaffolds
  • Natural product discovery
  • Fragment-based discovery
  • Macrocyclic inhibitors
  • Covalent inhibitors
  • Allosteric modulators
  • Lead optimization

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is October 2, 2015

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:
Kip Harry
Conference Director
Cambridge Healthtech Institute
Phone: (+1) 781-972-5454
Email: kharry@healthtech.com

For partnering & sponsorship information, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412
Email: cbenton@healthtech.com